CRC Research Update — September 03, 2026
Today's colorectal cancer research highlights
kras
A collection of 71 issues
HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer
Skip to content
The CRC Digest
HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer
A case report describes a significant response in a 54-year-old male with HER2-amplified, KRAS G12D-mutated metastatic rectal cancer treated with a zanidatamab-based combination regimen. (Frontiers in Immunology)
This content is informational only and does not constitute
CRC Research Update — September 02, 2026
Today's colorectal cancer research highlights
Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer
Skip to content
The CRC Digest
◇ RESEARCH
Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer
While approved KRAS therapies target only the rare G12C mutation, new drugs including MRTX1133, zoldonrasib, and daraxonrasib are being developed to directly target G12D and G12V—the most common
CRISPR-Cas9 electroporation targets KRAS G12V mutation in CRC cells
Skip to content
The CRC Digest
◇ RESEARCH
CRISPR-Cas9 electroporation targets KRAS G12V mutation in CRC cells
Researchers used direct electroporation of Cas9 ribonucleoproteins to achieve allele-specific disruption of KRAS p.G12V in SW480 colorectal cancer cells, assessing delivery efficiency and on-target editing. (Iranian Journal of Basic Medical Sciences)
This content
CRC Research Update — September 01, 2026
Today's colorectal cancer research highlights
Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer
The phase 3 ANCHOR trial (NCT04854668) compared CapeOX chemotherapy combined with anlotinib versus CapeOX combined with bevacizumab in patients with RAS/BRAF wild-type mCRC, evaluating
CRC Research Update — August 31, 2026
Today's colorectal cancer research highlights
Plant-derived formulation disrupts metabolism in KRAS-mutant colorectal and pancreatic cancer cells
Skip to content
The CRC Digest
Plant-derived formulation disrupts metabolism in KRAS-mutant colorectal and pancreatic cancer cells
A Lepidium latifolium formulation induced cell death and metabolic disruption in KRAS-mutant cancer models through iron-dependent mechanisms. (Molecules)
This content is informational only and does not constitute medical advice.
Always consult your oncologist
CRC Research Update — August 30, 2026
Today's colorectal cancer research highlights